AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00677937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified DESMOND education and ongoing support
Description: 6 hours of education with 1 month of inclusion, 3 years of ongoing support including annual refresher sessions
Study NCT01992172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Photocil for Atopic Dermatitis
Description: Photocil for Atopic Dermatitis
Study NCT01992172 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Sunscreen (SPF 2)
Description: Placebo - Sunscreen (SPF 2)
Study NCT00315458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch applied for 7-day wear.
Study NCT00315458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal patch
Description: Placebo to match buprenorphine transdermal patch 10 or 20.
Study NCT01807754 — intervention group
Intervention type: PROCEDURE
Intervention: X-ray and ultrasound imaging scanning
Description: Digital tomosynthesis mammogram uses a low radiation dose, taking x-ray pictures of the breast from many angles to make a 3D(dimensional)image. The participant will be seated and her breast positioned as in a normal mammogram, though with reduced pressure. The x-ray tube will move quickly above the breast to take the images. Then, an ultrasound scan will be done using gel on your breast to assist in acquiring quality imaging.
Study NCT01807754 — intervention group
Intervention type: PROCEDURE
Intervention: Photoacoustic imaging scans for breast cancer screening
Description: The participant will be seated in front of the laser device with the breast positioned on the laser device platform. Each subject will be given a laser protective eye mask/goggles to wear and will be instructed how to wear the mask/goggles during the scan. In addition pulse monitor leads may be placed on the participant's chest to allow the computer to record ultrasound blood flow in the breast. The low intensity laser light will be focused on the targeted area of the breast.
Study NCT02291042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B+O Suppository
Study NCT01229995 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dental implants - zirconia abutmetns - prefabricated abutments
Study NCT02433184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept will be administered subcutaneously at a dose of 50 mg weekly and will be discontinued at the primary endpoint (48 weeks).
Study NCT02433184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate will be administered orally at a starting dose of 15 mg and will be increased to 25mg weekly at 2 weeks.
Study NCT02433184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: Sulfasalazine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered orally at a dose of 1g twice daily. Will be discontinued if starting etanercept at 24 weeks.
Study NCT02433184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered at a dose of 200mg daily. Will be discontinued if starting etanercept at 24 weeks.
Study NCT02433184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Etanercept will be added at 24 weeks, if a subject fails to achieve clinical remission,at a dose of 50 mg weekly and will be discontinued at 48 weeks with the exception of those patients who are eligible to continue according to local prescribing guidelines (NICE guidelines)
Study NCT02433184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered orally at a starting dose of 15 mg weekly, increasing to 20mg and 25mg weekly at weeks 4 and 8 respectively.
Study NCT02550561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior Tibial Nerve Stimulation
Description: PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots.
Study NCT01822860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg
Study NCT01822860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Study NCT01822860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02632149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PINS Vagus Nerve Stimulator
Study NCT02283814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Study NCT02283814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topamax
Study NCT01797146 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Reminder and Evaluation Program
Description: This intervention will be implemented by ward nurses and responsible physicians. The details of intervention are shown below.~1. Nurse: Every morning, a ward nurse will check if any patient has a urinary catheter or a central venous catheter in place. An order sheet will be marked with a CARE-rubber stamp and the following information will be added by hand-writing.~   * Type and duration of urinary catheter use.~  * Indication of urinary catheter _________~  * Type and duration of central venous catheter use~  * Indication of urinary catheter _________~2. Responsible physician: During a morning round, a physician needs to fill the indication of catheter use. If a given physician does not fill the indication of urinary catheter use, the catheter will be automatically removed. If a given physician does not fill the indication of central venous catheter, the CARE team will be notified.
Study NCT02696850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Participants will undergo 4-week treatment course that includes budesonide powder added to saline rinse.
Study NCT02696850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline alone
Description: Participants will undergo 4-week treatment course that includes lactose (placebo) powder added to saline rinse.
Study NCT01016795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-metHuSCF and Filgrastim
Description: Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
Study NCT01016795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy plus Filgrastim
Description: Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
Study NCT00618514 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bright Tip Laser Fiber
Description: Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber with a fitted ceramic tip on the end. Treatment performed on one leg.
Study NCT01466673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol/Norgestimate (EE/NGM)
Description: Ethinyl estradiol/Norgestimate encapsulated oral tablet will be administered once daily at bed time as 0.035/0.18 milligram (mg) for Days 1-7, 0.035/0.215 mg for Days 8-14, and 0.035/0.250 mg for Days 15-21 of EE/NGM, respectively up to 6 consecutive menstrual cycles consisting of 21 days each.
Study NCT01466673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinyl estradiol/Desogestrel (EE/DSG)
Description: Ethinyl estradiol/Desogestrel oral formulation will be administered once daily at bed time as 0.040/0.025 mg for Days 1-7, 0.030/0.125 mg for Days 8-22 of EE/DSG, respectively up to 6 consecutive menstrual cycles consisting of 22 days each.
Study NCT00921765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline single bolus dose followed by saline single bolus dose iv
Study NCT00618514 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare Tip Laser Fiber
Description: Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber readily available on the market with a bare tip on the end. Treatment performed on one leg.
Study NCT00921765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline + Ketamine
Description: Single bolus dose of saline followed by ketamine 0.2 mg/kg bw
Study NCT00921765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone + Placebo
Description: Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
Study NCT00921765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone + Ketamine
Description: Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
Study NCT02007746 — intervention group
Intervention type: OTHER
Intervention: Liver transient elastography (Fibroscan)
Description: Fibroscan will be performed as a measure of liver stiffness. The study will be obtained free of charge in this study.
Study NCT01760954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix tablets administered orally
Study NCT03855722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: Remote Ischaemic Preconditioning
Study NCT03855722 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-RIPC
Description: Sham procedure
Study NCT02627677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 30 mg QD
Description: Ponatinib 30 mg, taken orally once daily.
Study NCT02627677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 15 mg QD
Description: Ponatinib 15 mg, taken orally once daily.
Study NCT02627677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib 400 mg BID
Description: Nilotinib 400 mg, taken orally twice daily.
Study NCT01954654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-made compression sleeve and -gauntlet
Description: Device: Compression garments worn for a minimum of six hours per day
Study NCT01954654 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Custom-made compression sleeve and -gauntlet
Description: Device: Compression garments worn for a minimum of six hours per day
Study NCT01954654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational information, recommendation and instruction
Description: Educational information and recommendations about lymphedema and skin care. Instruction in physical exercises to enhance the lymph flow
Study NCT01954654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational information, recommendation and instruction
Description: Educational information and recommendations about lymphedema and skin care. Instruction in physical exercises to enhance the lymph flow
Study NCT02837744 — intervention group
Intervention type: DEVICE
Intervention: Axiostat®
Description: Axiostat Chitosan Hemostatic dressing belongs to an advanced class of wound dressing that stops bleeding within few minutes of application by providing an active mechanical barrier.
Study NCT02886572 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Description: Linear-accelerator-based, single-isocenter, image-guided stereotactic radiosurgery
Study NCT01153633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prontosan Wound Irrigation Solution and Prontosan Wound Gel
Description: The treatment procedures (after a 1 week run-in) include:~* Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~* Secondary dressing to be a semi occlusive dressing~* Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change.
Study NCT01153633 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline and Placebo Gel
Description: The treatment procedures (after a 1 week run-in) include:~* Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~* Secondary dressing to be a semi occlusive dressing~* Secure the dressing to the wound with tubifast and short stretch compression system~Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change.
Study NCT03783169 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular Sonographic Assessment
Description: Maternal sonographic vascular measurements assessing volume status, cardiac output, and systemic vascular resistance by means of inferior vena cava collapsibility/caval index (ICV CI), end-point septal separation (EPSS) for determining left ventricular ejection fraction (LVEF), cardiac output determination (stroke volume x heart rate), stroke volume variation, \& radial artery resistance index) augments standard vital sign assessment (pulse pressure and systolic / diastolic predominance)
Study NCT02007746 — intervention group
Intervention type: OTHER
Intervention: Ferriscan
Description: Ferriscan will be done to assess the quantity of liver iron in iron overloaded subjects.
Study NCT02007746 — intervention group
Intervention type: PROCEDURE
Intervention: Liver biopsy in iron overloaded subjects.
Description: Liver biopsy will be done and the results will be compared to Fibroscan results.
Study NCT03153059 — intervention group
Intervention type: OTHER
Intervention: Stool frequency
Description: This study is just observational study.
Study NCT03745573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empateach
Description: Empateach is a behavioural intervention for teachers.
Study NCT03434626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP Education
Description: Decision aid and Goals of Care Designation form information administered by Navigator
Study NCT03434626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care includes reviewing Goals of Care Designation form and Greensleeve with physician
Study NCT03434626 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care includes reviewing Goals of Care Designation form and Greensleeve with physician
Study NCT03224117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ211
Description: inject the Drug into submental fat via subcutaneous
Study NCT03224117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: inject the Drug into submental fat via subcutaneous
Study NCT03682627 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fenestration
Description: A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The peritoneal will not be sutured at the edges to keep the fenestration open. No interpositioning of the omentum will be performed.
Study NCT03682627 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fenestration and clipping
Description: A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The window edges will be clipped after fenestration using 8 metal clips.
Study NCT00450177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Description: Iron group
Study NCT00450177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo group
Study NCT03933982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Plus Vinorelbine
Description: Pyrotinib: 320mg/d, q.d., p.o. A course of treatment need 21 days. Vinorelbine: 60mg/m2 q.d. d1,8,15, p.o. A course of treatment need 21 day.
Study NCT01570218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days
Study NCT03996382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: DPD Scintigraphy
Description: Confirms/Refutes diagnosis of cardiac amyloidosis.
Study NCT05123248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blinded Group
Description: Participants in the blinded group will be wearing the sensor for 14 days without a reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. After 14 days, participants are required to scan the sensor themselves or with the assistance of a CRC to a designated blinded-reader.
Study NCT05123248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unblinded group
Description: Participants in the non-blinded group are required to wear the CGM sensor for 14 days with an open reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. The participant will be required to upload their glucose readings no longer than 8 hours by scanning the reader provided.
Study NCT02919579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Intranasal)
Description: Participants will receive intranasal placebo in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
Study NCT02919579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will receive intranasal esketamine in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
Study NCT02919579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Participants will receive oral alcohol in Part A (as per the treatment sequence in period 1,2 and 3).
Study NCT02919579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Oral)
Description: Participants will receive oral placebo in Part A (as per the treatment sequence in period 1,2 and 3).
Study NCT01205269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683, 50 mcg
Description: Dry powder for inhalation, single dose
Study NCT01205269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dry powder for inhalation, single dose
Study NCT02391402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitively Augmented Behavioral Activation
Description: CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
Study NCT02391402 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need.